At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
SJP-0132 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Single-Center, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of SJP-0132 in Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating SJP-0132 and Placebo for Dry Eye Disease and Dry Eye Syndrome. Completed, enrolled 89 participants across 1 site.
Detailed Summary
This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease, Dry Eye Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedOct 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedOct 25, 2019
Enrollment StartOct 5, 2019
Primary CompletionMar 3, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.7 years ago
Interventions
SJP-0132drug
SJP-0132 is administered as an eye drop
Placebodrug
Placebo is administered as an eye drop